Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409119 | 0.85 | CNR2 (0.49) | CNR2TRPV1MAPTIDEALDH1A1 | |
| SCHEMBL4404533 | 0.81 | CNR2 (0.47) | CNR2TRPV1MAPTIDEALDH1A1 | |
| SCHEMBL4408212 | 0.80 | CNR2 (0.46) | CNR2TRPV1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4406055 | 0.80 | CNR2 (0.51) | CNR2TRPV1MAPTIDEALDH1A1 | |
| SCHEMBL4407849 | 0.80 | CNR2 (0.51) | CNR2TRPV1MAPTIDEALDH1A1 | |
| SCHEMBL4409002 | 0.79 | CNR2 (0.44) | CNR2TRPV1MAPTALDH1A1LMNA | |
| SCHEMBL7413802 | 0.78 | CNR2 (0.50) | CNR2TRPV1MAPTIDEALDH1A1 | |
| SCHEMBL6473514 | 0.78 | ALDH1A1 (0.38) | CNR2MAPTIDEALDH1A1KMT2A | |
| SCHEMBL4407077 | 0.77 | CNR2 (0.49) | CNR2TRPV1MAPTIDEALDH1A1 | |
| SCHEMBL96673 | 0.76 | IDE (0.38) | CNR2MAPTIDEALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | CNR2 3483/4885TRPV1 1406/4885MAPT 657/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | CNR2 3483/4885TRPV1 1406/4885MAPT 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.